Hair typically begins falling out 2 to 4 weeks after your first chemotherapy session. The exact timing depends on the drug, the dose, and your individual biology, but most people notice the first signs of shedding within that window. Not all chemotherapy drugs cause hair loss, and among those that do, the severity ranges from mild thinning to complete loss across the scalp and body.
What the First Few Weeks Look Like
Before hair actually starts falling out, many people notice their scalp feeling tender, tingly, or unusually sensitive. This can begin a few days before the shedding starts and is a signal that the hair follicles are being affected. When the loss begins, it often feels sudden. You might find clumps on your pillow, in the shower drain, or coming out when you run your fingers through your hair. For some people the shedding is more gradual, but the 2-to-4-week mark is when the process visibly starts for most.
Chemotherapy works by attacking cells that divide rapidly. Cancer cells divide rapidly, but so do the cells in your hair follicles. Your hair follicles are among the fastest-growing cells in the body, which is why they’re so vulnerable to these drugs. The extent of the damage depends on how severely the treatment disrupts the growth cycle of the follicle and whether it harms the deeper stem cells responsible for regenerating hair.
Eyebrows, Eyelashes, and Body Hair
Scalp hair is usually the first to go, but eyebrows, eyelashes, and body hair can follow. This often catches people off guard because it can happen weeks or even months after scalp hair has already fallen out. The delay occurs because hair in these areas grows on a different, slower cycle than scalp hair. Not everyone loses eyebrows and lashes, but if your treatment causes complete scalp hair loss, there’s a reasonable chance other hair will thin or fall out too.
Which Treatments Cause the Most Hair Loss
Not every chemotherapy drug causes significant hair loss. Some cause only mild thinning, and some cause none at all. The drugs most strongly associated with complete hair loss are certain classes used in breast cancer treatment and other common cancers. There’s no reliable way to predict beforehand exactly how much hair you’ll lose on a given regimen.
Other cancer treatments affect hair differently. Targeted therapy drugs tend to cause gradual thinning rather than sudden loss. Hormone therapy typically causes thinning as well. Immunotherapy varies widely depending on the specific drug. Complete hair loss is almost exclusively a chemotherapy side effect.
Scalp Cooling Can Help Some People Keep Their Hair
Scalp cooling systems, which are cold caps worn during infusion sessions, work by constricting blood vessels in the scalp and reducing how much drug reaches the hair follicles. A 2025 clinical trial of breast cancer patients receiving a particularly aggressive regimen (four cycles of one drug class followed by four cycles of another) found that roughly 73 to 75% of patients who used scalp cooling retained enough hair to avoid needing a wig. The caps need to be worn before, during, and after each infusion, and they can cause headaches and discomfort from the cold, but for many people the trade-off is worth it.
When Hair Grows Back
For most people, hair starts returning within weeks of finishing treatment. The typical timeline looks like this: around 6 weeks after your last session, fine, soft fuzz appears on the scalp. Between 3 and 6 months, fuller and more visible regrowth takes over. Many people have enough hair by the 6-month mark to stop wearing a head covering if they choose to.
The hair that grows back initially is often different from what you had before. It may come in curlier, wavier, darker, lighter, or with a different texture. This is commonly called “chemo curls.” These changes are usually temporary. As the months pass and the drugs fully clear your system, hair gradually returns to its original color, texture, and thickness for most people.
The Risk of Permanent or Long-Lasting Hair Loss
Most chemotherapy-related hair loss is fully reversible, but a meaningful percentage of people experience what’s called persistent hair loss, defined as incomplete or absent regrowth six months or more after finishing treatment. The risk varies dramatically by drug regimen.
Certain drug combinations carry a notably higher risk. Regimens containing doxorubicin (a common breast cancer drug) have been linked to persistent thinning in up to 67% of patients in some studies. Docetaxel-based combinations can produce persistent hair loss in up to 52% of patients, particularly when combined with other agents in multi-drug regimens. Sequential treatment plans that use one class of drug followed by another tend to carry higher risk than single-agent approaches, likely because of the cumulative exposure the follicles endure.
The key factors that increase the chance of lasting hair changes include the total amount of drug received, how intensely the doses are spaced, and which specific drugs are used in combination. For many of these patients, hair does eventually improve further beyond the six-month mark, but it may never fully return to its pre-treatment density. If you’re concerned about this possibility, your oncology team can tell you where your specific regimen falls on the risk spectrum.